triazoles has been researched along with istradefylline in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beilstein, M; Castagnoli, K; Castagnoli, N; Chen, JF; Petzer, JP; Schwarzschild, MA; Sonsalla, PK; Staal, R; Xu, K; Xu, YH | 1 |
| Bertorelli, R; Costentin, J; El Yacoubi, M; Ledent, C; Ongini, E; Parmentier, M; Vaugeois, JM | 1 |
| Harvey, V; Jones, J; Knight, AR; Misra, A; Quirk, K | 1 |
| Abbracchio, MP; Brambilla, R; Ceruti, S; Cottini, L; Fumagalli, M | 1 |
| Gianfriddo, M; Melani, A; Pedata, F; Pugliese, AM | 1 |
| Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L | 1 |
| Costentin, J; El Yacoubi, M; Vaugeois, JM | 1 |
| Benwell, K; Cliffe, IA; Dourish, CT; Gillespie, RJ; Knight, AR; Lerpiniere, J; Misra, A; Pratt, RM; Revell, D; Upton, R; Weiss, SM | 1 |
| Alexander, SP; Beckett, SR; Harper, LK; Marsden, CA; McCreary, AC | 1 |
| Belardinelli, L; Chu, N; Diamond, I; Kalla, R; Leung, K; Shryock, JC; Soelaiman, S; Soohoo, D; Yang, M; Yao, L; Zablocki, J | 1 |
| Canas, PM; Cunha, GM; Cunha, RA; Hockemeyer, J; Melo, CS; Müller, CE; Oliveira, CR | 1 |
| Grzelak, ME; Hodgson, RA; Hunter, JC; Parker, EM; Pond, AJ; Varty, GB | 1 |
| Agostinho, PM; Cognato, GP; Cunha, RA; Hockemeyer, J; Müller, CE; Souza, DO | 1 |
| Kincses, ZT; Szabó, N; Vécsei, L | 1 |
| Arnau, JM; Ciruela, F; Fernandez-Duenas, V; Pedros, C; Vallano, A | 1 |
| Han, K; Pang, X; Yang, M | 1 |
| Filip, M; Fuxe, K; Gołembiowska, K; Kamińska, K; Suder, A; Wydra, K | 1 |
| Downey, P; Michel, A; Nicolas, JM; Scheller, D | 1 |
| Borroto-Escuela, DO; Franco, R; Fuxe, K; Navarro, G | 1 |
| Bonaventura, J; Brugarolas, M; Casadó, V; Cellai, L; Chang, CP; Chern, Y; Cortés, A; Dettori, I; Ferré, S; Guitart, X; Narayanan, M; Orrú, M; Pedata, F; Rea, W | 1 |
| Ishibashi, K; Ishii, K; Ishiwata, K; Miura, Y; Toyohara, J; Wagatsuma, K | 1 |
3 review(s) available for triazoles and istradefylline
| Article | Year |
|---|---|
Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Central Nervous System; Clinical Trials as Topic; Dopamine; Humans; Neuroprotective Agents; Parkinson Disease; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazoles | 2011 |
An update on adenosine A2A receptors as drug target in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Humans; Molecular Targeted Therapy; Parkinson Disease; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazoles | 2011 |
Purinergic signaling in Parkinson's disease. Relevance for treatment.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Basal Ganglia; Corpus Striatum; Humans; Parkinson Disease; Purine Nucleotides; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Signal Transduction; Triazoles | 2016 |
1 trial(s) available for triazoles and istradefylline
| Article | Year |
|---|---|
Occupancy of adenosine A
Topics: Adenosine A2 Receptor Antagonists; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Brain Mapping; Carbon Radioisotopes; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Purines; Pyrimidines; Radiopharmaceuticals; Receptor, Adenosine A2A; Triazoles | 2018 |
17 other study(ies) available for triazoles and istradefylline
| Article | Year |
|---|---|
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Catechols; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Immunity, Innate; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Purinergic P1; Theobromine; Triazoles; Xanthines | 2001 |
Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blepharoptosis; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Immobilization; Male; Mice; Mice, Knockout; Motor Activity; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Receptors, Purinergic P1; Reserpine; Swimming; Time Factors; Triazoles | 2001 |
Solubilisation and immunoprecipitation of rat striatal adenosine A(2A) receptors.
Topics: Adenosine; Animals; Cholic Acids; Corpus Striatum; Detergents; Phenethylamines; Precipitin Tests; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Radioligand Assay; Rats; Receptor, Adenosine A2A; Receptors, Purinergic P1; Solubility; Triazines; Triazoles | 2001 |
Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Animals, Newborn; Astrocytes; Cell Division; Cells, Cultured; Cerebral Cortex; Corpus Striatum; Dose-Response Relationship, Drug; Drug Interactions; Fibroblast Growth Factor 2; Fluorescent Antibody Technique; Glial Fibrillary Acidic Protein; Gliosis; Neuroprotective Agents; Phenethylamines; Purines; Pyrimidines; Rats; Receptor, Adenosine A2A; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles; Vasodilator Agents | 2003 |
A2A receptors in neuroprotection of dopaminergic neurons.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Neurons; Neuroprotective Agents; Parkinson Disease; Purines; Pyrimidines; Receptor, Adenosine A2A; Sex Factors; Triazoles | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles | 2003 |
Adenosine A2A receptors and depression.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caffeine; Depression; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Haloperidol; Mice; Mice, Knockout; Motor Activity; Neurotransmitter Agents; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazines; Triazoles | 2003 |
Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mefloquine; Mice; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Phenethylamines; Purines; Pyrimidines; Radioligand Assay; Rats; Triazines; Triazoles | 2003 |
Effects of the A 2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo.
Topics: Animals; Binding, Competitive; Conditioning, Operant; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; gamma-Aminobutyric Acid; In Vitro Techniques; Male; Microdialysis; Motor Activity; Nucleus Accumbens; Purines; Rats; Receptor, Adenosine A2A; Triazines; Triazoles; Xanthines | 2006 |
Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Animals; Binding, Competitive; Biological Availability; Cell Line; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Male; Metabolic Clearance Rate; Molecular Structure; PC12 Cells; Phenethylamines; Purines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptor, Adenosine A3; Theobromine; Triazines; Triazoles; Xanthines | 2007 |
Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801.
Topics: Adenosine A2 Receptor Antagonists; Amyloid beta-Peptides; Analysis of Variance; Animals; Behavior, Animal; Dizocilpine Maleate; Drug Interactions; Male; Maze Learning; Memory Disorders; Motor Activity; Neuroprotective Agents; Peptide Fragments; Purines; Pyrimidines; Rats; Rats, Wistar; Scopolamine; Triazoles | 2008 |
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Caffeine; Catalepsy; Cebus; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Haloperidol; Neurologic Examination; Purines; Pyrimidines; Receptor, Adenosine A2A; Saimiri; Triazoles; Xanthines | 2008 |
Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Animals, Newborn; Caffeine; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Glial Fibrillary Acidic Protein; Kainic Acid; Memory Disorders; Neurotoxicity Syndromes; Phosphodiesterase Inhibitors; Purines; Pyrimidines; Qa-SNARE Proteins; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Seizures; Synapses; Synaptophysin; Synaptosomal-Associated Protein 25; Triazoles; Tritium; Xanthines | 2010 |
Antagonist binding and induced conformational dynamics of GPCR A2A adenosine receptor.
Topics: Adenosine A2 Receptor Antagonists; Animals; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Conformation; Purines; Rats; Receptor, Adenosine A2A; Thermodynamics; Triazines; Triazoles | 2013 |
On the role of adenosine (A)₂A receptors in cocaine-induced reward: a pharmacological and neurochemical analysis in rats.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Basal Forebrain; Behavior, Animal; Cocaine; Cocaine-Related Disorders; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Male; Nucleus Accumbens; Phenethylamines; Purines; Pyrimidines; Rats; Rats, Wistar; Receptor, Adenosine A2A; Reinforcement, Psychology; Reward; Self Administration; Triazoles | 2015 |
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Benzothiazoles; Drug Therapy, Combination; Levodopa; Mass Spectrometry; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Purines; Pyrimidines; Rats; Receptors, N-Methyl-D-Aspartate; Triazoles | 2014 |
Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Biomarkers; Corpus Striatum; Disease Models, Animal; Gene Expression Regulation; Humans; Huntingtin Protein; Huntington Disease; Locomotion; Nucleoside Transport Proteins; Prefrontal Cortex; Psychomotor Disorders; Purines; Rats; Rats, Transgenic; Receptor, Adenosine A2A; Triazines; Triazoles; Trinucleotide Repeat Expansion; Tritium | 2016 |